Conditions: Alzheimer's Disease
Keywords: Efficacy Safety Pharmacokinetics Alzheimer's disease
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 66
Healthy volunteers: no

Brief summary:
1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease
2. Evaluate the effects of varenicline on clinically relevant measures including attention and executive function, behavior, and clinician rated global change.
3. Evaluate the safety and tolerability of varenicline, relative to placebo, in patients with mild to moderate Alzheimer's disease
4. Evaluate the pharmacokinetics of varenicline in patients with mild to moderate Alzheimer's disease.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Varenicline intervention 2: Placebo
Intervention descriptions: intervention 1: 0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks intervention 2: Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.

Protocol document: